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Summary
Background: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous
coronary intervention (PCI). This study aimed to evaluate the relationship between the degree
of renal function at baseline and long-term clinical outcomes in coronary artery disease patients
who underwent paclitaxel-eluting stent implantation.
Methods: A total of 336 patients with 400 de-novo lesions underwent PCI between May 2007 and
March 2009. The patients were divided into 4 groups: control (glomerular ﬁltration rate (GFR)
90ml/min; n = 132); mild CKD (GFR 60—89ml/min; n = 112); moderate CKD (GFR <60ml/min;
n = 51); and dialysis (n = 41). All lesions were treated using a paclitaxel-eluting stent. The pri-
mary and secondary endpoints were incidences of mortality and major adverse cardiovascular
events (MACE) during 2 years after PCI and target vessel revascularization (TVR), respectively.
Results: Two-year MACE incidence rates were 9.7%, 15.2%, 30%, and 31% in control, mild CKD,
moderate CKD, and dialysis groups, respectively. TVR trended upward with increasing renal
impairment (8.3%, 12.5%, 18%, and 21.4% for the 4 groups, respectively, p = 0.09). Mild CKD,
moderate CKD, and dialysis patients had adjusted hazard ratios of 2.51 (95% CI, 1.01—6.24);
3.20 (95% CI, 1.07—9.60); and 4.19 (95% CI, 1.30—13.51), respectively, for 2-year MACE.
Conclusions: A graded relationship was observed between lower renal function and increased
TVR, although it did not reach statistical signiﬁcance. Cardiac death and TVR rates were signiﬁ-
cantly higher in moderate CKD and dialysis patients after paclitaxel-eluting stent implantation.
Patients with reduced renal fun
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hronic kidney disease (CKD) has been recognized as an
mportant comorbidity factor in coronary artery disease
CAD) patients [1,2]. Multiple data have demonstrated that
Published by Elsevier Ltd. All rights reserved.
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KD is associated with increased risks of major adverse
ardiovascular events (MACE) and mortality after percu-
aneous coronary intervention (PCI) [3—5]. Most studies
eﬁned CKD, as a fall in the serial estimated glomerular
ltration rate (GFR) below 60ml/min/1.73m2 [6—10]. How-
ver, renal function in CAD patients varies widely, ranging
rom subclinical renal insufﬁciency to dialysis. Therefore,
atients with different levels of renal function may show
ifferent clinical outcomes after coronary intervention using
he same stent. Drug-eluting stents (DESs) are widely used in
linical practice due to excellent outcomes with low rates of
arget vessel revascularization (TVR) at long-term follow-up
11]. Previous studies have reported that sirolimus-eluting
tent implantation decreased the risk of repeat revascular-
zation in CKD patients, but it did not decrease the mortality
isk after PCI [7—9]. Still, the efﬁcacy of paclitaxel-eluting
tents has not been established for severe CKD and dialysis
atients. Therefore, the aim of this study was to evaluate
he relationship between degree of renal function at base-
ine and long-term clinical outcomes in CAD patients who
nderwent paclitaxel-eluting stent implantation.
ethods
atient population and classiﬁcation
his retrospective analysis comprised of only patients
ndergoing paclitaxel-eluting stent implantation (Taxus;
oston Scientiﬁc, Boston, MA, USA) at our hospital between
ay 2007 and March 2009. The following patients were
xcluded from the study: (1) patients with an in-stent
estenosis lesion; and (2) patients who were treated with
irolimus-eluting or bare-metal stents. Finally, we found
total of 336 patients with 400 de-novo lesions who
ad successful paclitaxel-eluting stent implantation. Crea-
inine clearance was calculated using the Cockroft—Gault
quation by considering parameters, such as age, sex,
eight, and serum creatinine level, to estimate renal
unction [12]. Based on the Kidney Disease Outcomes
uality Initiative guidelines, CKD stages of the patients
ere further categorized as follows: stage1, normal
r increased GFR (90ml/min/1.73m2); stage 2, mild
ecreased GFR (60—89ml/min/1.73m2); stage 3, mod-
rately decreased GFR (30—59ml/min/1.73m2); stage 4,
everely decreased GFR (15—29ml/min/1.73m2); stage 5,
idney failure (<15ml/min/1.73m2) [13]. CKD stages 4 and
were considered as a single group because only 2 patients
ere categorized as CKD stage 4. All patients with CKD
tage 5 were on hemodialysis. Finally, the patients were
ivided into the following 4 groups and analyzed: control
GFR 90ml/min; n = 132); mild CKD (GFR 60—89ml/min;
= 112); moderate CKD (GFR 59—20ml/min; n = 51); and
ialysis (n = 41).
tent and post-procedural managementbolus of heparin (100 IU/kg) was administered after sheath
nsertion and titrated to maintain an activated clotting time
f >250 s throughout the procedure. Paclitaxel-eluting stent
as positively used in our hospital during the period if not
ontraindicated; for example, for patients with planned sur-
(
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f
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ical operations or with malignancies. Target lesions were
redilated using conventional angioplasty balloons. After
tent implantation, high-pressure balloon inﬂation was per-
ormed to achieve a satisfactory angiographic result of less
han 25% residual stenosis by visual estimate. All patients
eceived aspirin 100mg plus clopidogrel 75mg per day for at
east 12 months and other cardiac medications as prescribed
y the physicians.
ollow-up and deﬁnitions
he primary endpoints of the study were incidences of
ardiac death and MACE (combined incidence of cardiac
eath, myocardial infarction, or TVR) during 2 years after
CI. The secondary endpoints were TVR and angiographic
n-stent late luminal loss. All patients were scheduled to
ndergo follow-up angiography at 8 months after PCI. Clin-
cal follow-up conducted for all patients included hospital
isits and phone interviews at 30 days and 2 years after PCI.
uantitative coronary angiography was performed before,
mmediately, and 8 months after the procedure using edge
etection algorithms. Minimal lumen diameter (MLD), refer-
nce vessel diameter, diameter stenosis, and lesion length
ere measured using a single matched worst view. Late
umen loss was deﬁned as the difference between MLD
mmediately after the procedure and that at 8 months
fter PCI. Angiographic restenosis was deﬁned as diame-
er stenosis >50% by quantitative coronary angiography at
months after PCI. TVR was deﬁned as coronary artery
ypass surgery involving the target vessel or PCI performed
n the target lesion due to myocardial ischemia, combined
ncidence of death or myocardial infarction, or the inci-
ence of stent thrombosis. Stent thrombosis was considered
o have occurred when angiography conﬁrmed the pres-
nce of either Thrombolysis in Myocardial Infarction (TIMI)
ow grade 0 or 1, or ﬂow-limiting thrombus occurring at
ny time after stent implantation [14]. The diagnosis of
yocardial infarction required the presence of new Q-waves
n electrocardiogram (ECG) and/or elevation of creatine
inase-MB isoenzyme (or total creatine kinase if creatine
inase-MB was not available) 2 times the upper limit
f the normal range [15]. The patients who had cardiac
omplaints underwent a complete clinical, electrocardio-
raphic, and laboratory evaluations. All patients provided
ritten informed consent.
tatistical analysis
he data are presented as mean± SD or counts (%). Differ-
nces between groups were assessed using the ANOVA test
or continuous variables. Categorical data were compared
sing the Chi-square test. Event-free survival analyses were
erformed using the Kaplan—Meier method. Differences
n cumulative adverse cardiac event rates and mortality
ere assessed using the log-rank test. The unadjusted and
djusted risks of MACE were assessed using hazard ratios
HRs) and 95% conﬁdence intervals (CIs) derived from uni-
ariate and multivariate Cox regression models. To adjust
or baseline differences, potentially relevant variables were
ntered into models if they showed univariable differences
mong the 4 groups with a p-value < 0.05.
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Table 1 Baseline characteristics.
Control
(n = 132)
Mild CKD
(n = 112)
Moderate
CKD (n = 51)
Dialysis
(n = 41)
p* p#
Age (years) 67± 10 71± 8 75± 9 70± 8 <0.0001 0.001
Women, n 24 (18) 24 (21) 23 (45) 7 (17) <0.001 0.01
Body weight (kg) 63.5± 11.4 63.7± 11.2 58.9± 9.7 58.6± 11.6 0.01 <0.001
Body mass index (kg/m2) 23.9± 3.5 24.4± 3.4 24.0± 3.1 23.0± 4.8 0.25 0.22
Diabetes, n 46 (35) 46 (41) 35 (69) 24 (59) 0.0001 <0.0001
Insulin, n 4 (3) 12 (11) 15 (29) 11 (27) <0.0001 <0.0001
Hypertension, n 96 (73) 93 (83) 45 (88) 40 (98) 0.003 0.002
Hypercholesterolemia, n 80 (61) 73 (65) 36 (70) 18 (44) 0.08 0.43
Prior myocardial infarction, n 41 (31) 38 (34) 27 (53) 16 (39) 0.06 0.02
Prior coronary artery bypass
surgery, n
7 (5) 6 (5) 1 (2) 3 (7) 0.66 0.99
Estimated glomerular ﬁltration
rate (ml/min)
107.9± 16.2 75.3± 8.8 46.2± 9.7 10.8± 4.0 <0.0001 <0.0001
Hemoglobin (g/dl) 13.7± 1.6 13.0± 1.8 11.7± 2.1 10.5± 2.0 <0.0001 <0.0001
Clinical presentation
Stable angina, n 79 (60) 64 (57) 33 (65) 25 (61) 0.83 0.53
Acute coronary syndromes, n 53 (40) 48 (43) 18 (35) 16 (39)
Left ventricular ejection
fraction (%)
60± 13 59± 12 55± 16 51± 18 <0.001 <0.0001
Multivessel disease, n 102 (77) 91 (81) 42 (82) 39 (95) 0.08 0.06
Treatment at discharge
Dual antiplatelet therapy 132 (100) 112 (100) 47 (94) 41 (100) <0.001 <0.001
Statins, n 120 (91) 102 (85) 38 (76) 26 (63) <0.0001 <0.0001
Beta-blockers, n 33 (25) 44 (39) 18 (36) 19 (46) 0.03 0.17
ACE-inhibitors, n 18 (14) 17 (15) 8 (16) 5 (12) 0.94 0.90
ARB, n 83 (63) 91 (81) 40 (80) 28 (68) 0.007 0.74
Oral hypoglycemic agents, n 24 (18) 32 (29) 18 (36) 11 (27) 0.60 0.14
Data are presented as number of patients (%) or mean± SD.
; ARB
≥60m
l
0
p
m
e
a
<
w
m
3
T
y
i
t
a
oCKD, chronic kidney disease; ACE, angiotensin-converting enzyme
* p-Value among all 4 groups.
# p-Value between glomerular ﬁltration rate (GFR) <60 and GFR
Results
The baseline clinical characteristics of the patients divided
into the 4 groups according to baseline GFR are shown in
Table 1. Here 27% of the study population had moderately
impaired renal function. As expected, several clinically rele-
vant characteristics proved to be more severe in the low GFR
groups. The patients in the low GFR groups were older than
those in the control group, and often had diabetes, hyper-
tension, prior myocardial infarction, and multiple coronary
vessel disease. A higher proportion of women were seen
in patients with moderate CKD. Moreover, the baseline
hemoglobin level and left ventricular ejection fraction were
signiﬁcantly lower in moderate CKD and dialysis patients.
At discharge, the patients with low GFR were less likely to
receive statins and angiotensin-II receptor blocking agents.
No differences were observed in terms of complex lesions
and procedural data among the 4 groups (Table 2). Notably,
no signiﬁcant differences were observed between control
and mild CKD patients in terms of clinical and angiographic
characteristics. The results of quantitative coronary angiog-
raphy before and immediately after the procedures were
not signiﬁcantly different among the 4 groups (Table 3).
After 8 months, however, differences were observed in
g
1
m
c
g, angiotensin-II receptor blockers.
l/min/1.73mm2.
ate lumen loss among the 4 groups (0.43, 0.60, 0.86, and
.86mm in control, mild CKD, moderate CKD, and dialysis
atients, respectively). Notably, late lumen loss between
oderate CKD and dialysis patients was identical. Differ-
nces in binary restenosis rates also remained signiﬁcant
mong the 4 groups, especially between the groups with GFR
60 and 60ml/min/1.73mm2 (30.4% vs. 12.8%, p = 0.002),
hereas no difference was observed between control and
ild CKD patients (11.8% vs. 14.1%, p = 0.76).
0-Day and 2-year clinical outcomes
he incidence of cardiac events at the ﬁrst 30 days and 2
ears after PCI is summarized in Table 4. The 30-day MACE
ncidence rate was 1.8% (n = 6) and was not different among
he 4 groups. Three cardiac deaths occurred in the moder-
te CKD group. Stent thrombosis during the ﬁrst 30 days was
bserved in 1 patient from both the control and mild CKD
roups. Two-year MACE incidence rates were 9.7% (n = 13),
5.2% (n = 17), 30% (n = 15), and 31% (n = 13) in the control,
ild CKD, moderate CKD, and dialysis groups (Fig. 1A). No
ardiac death was observed during 2 years in the control
roup, whereas 6 patients died (cardiac failure in 5 and sud-
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Table 2 Lesion and procedural characteristics.
Control
(n = 155)
Mild CKD
(n = 132)
Moderate
CKD (n = 58)
Dialysis
(n = 55)
p* p#
Target coronary artery 0.36 0.44
Left anterior descending 53 (34) 45 (34) 27 (46) 20 (37)
Right coronary artery 44 (28) 47 (36) 17 (29) 15 (28)
Left circumﬂex 41 (27) 25 (19) 11 (18) 9 (17)
Left main artery 17 (11) 15 (11) 4 (7) 10 (18)
Type B2/C lesions 113 (73) 104 (79) 50 (85) 41 (76) 0.29 0.36
Bifurcation lesion 64 (41) 58 (44) 26 (44) 26 (48) 0.85 0.58
Chronic total occluded lesion 17 (11) 20 (15) 6 (10) 4 (7) 0.44 0.3
TIMI ﬂow grade before intervention
0 28 (18) 23 (17) 9 (16) 4 (7) 0.22 0.31
1 5 (3) 4 (3) 2 (3) 0
2 14 (9) 10 (8) 7 (12) 1 (2)
3 108 (70) 95 (72) 40 (69) 50 (91)
TIMI ﬂow grade after intervention
2 2 (1) 0 1 (2) 0 0.43 0.84
3 153 (99) 132 (100) 57 (98) 55 (100)
Number of stents, n 1.5± 0.7 1.6± 0.7 1.6± 0.8 1.5± 0.8 0.69 0.55
Stent diameter (mm) 3.0± 0.4 3.0± 0.4 2.9± 0.4 3.0± 0.3 0.48 0.20
Stent length (mm) 35± 19 36± 20 34± 18 34± 20 0.90 0.48
Maximal inﬂation pressure (atm) 16± 4 16± 4 16± 4 17± 5 0.55 0.19
Data are presented as number of lesions (%) or mean± SD.
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# p-Value between glomerular ﬁltration rate (GFR) <60 and GFRen death in 1) in the moderate CKD group, and 2 patients
ied (cardiac failure in both) in the dialysis group (Fig. 1B).
difference was observed in TVR at 2 years after PCI among
he 4 groups. The revascularization rate by PCI revealed a
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Table 3 Quantitative coronary angiogram.
Control
(n = 155)
Mild
(n =
Before intervention
Vessel size (mm) 2.77± 0.60 2.7
Minimal lumen diameter (mm) 0.84± 0.50 0.7
Diameter stenosis (%) 69.9± 16.8 74.1
Lesion length (mm) 27.5± 15.9 29.1
After intervention
Vessel size (mm) 2.99± 0.58 2.9
Minimal lumen diameter (mm) 2.55± 0.55 2.6
Diameter stenosis after intervention (%) 12.1± 8.9 9.4
8 months after intervention
Follow up angiogram (%) 76.8 69.7
Vessel size (mm) 2.92± 0.50 2.7
Minimal lumen diameter (mm) 2.14± 0.62 2.0
Diameter stenosis after intervention (%) 26.6± 18.0 28.8
Acute gain (mm) 1.70± 0.67 1.8
Late lumen loss (mm) 0.43± 0.50 0.6
Binary restenosis (%) 11.8 14.1
Data are presented as number of lesions (%) or mean± SD.
CKD, chronic kidney disease.
* p-Value among all 4 groups.
# p-Value between glomerular ﬁltration rate (GFR) <60 and GFR ≥60n.
ml/min/1.73mm2.endency to increase as the CKD stage progressed (8.3%,
2.5%, 14%, and 19% in the control, mild CKD, moderate CKD,
nd dialysis groups, respectively, p = 0.27). Stent thrombosis
ccurred in 5 patients (1.5%) at 2 years after PCI. However,
CKD
132)
Moderate
CKD (n = 58)
Dialysis
(n = 55)
p* p#
4± 0.55 2.65± 0.54 2.81± 0.55 0.66 0.75
3± 0.48 0.80± 0.47 0.88± 0.42 0.19 0.08
± 16.3 68.8± 17.5 68.0± 15.1 0.10 0.06
± 17.4 29.4± 13.1 26.4± 16.4 0.72 0.87
3± 0.53 2.86± 0.50 3.10± 0.46 0.16 0.73
0± 0.53 2.60± 0.50 2.71± 0.49 0.38 0.20
± 8.0 9.9± 7.7 10.1± 7.9 0.09 0.14
53.4 69.1 0.01 0.02
8± 0.49 2.95± 0.45 2.91± 0.41 0.16 0.34
1± 0.72 1.83± 0.91 1.86± 0.77 0.07 0.02
± 21.1 39.5± 25.6 36.7± 24.1 0.006 0.0006
7± 0.64 1.79± 0.59 1.82± 0.53 0.23 0.70
0± 0.63 0.86± 0.62 0.86± 0.69 <0.0001 <0.0001
32.3 28.9 0.008 0.002
ml/min/1.73mm2.
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Table 4 Clinical outcomes at 30 days and 2 years after percutaneous coronary intervention.
All
(n = 336)
Control
(n = 132)
Mild CKD
(n = 112)
Moderate
CKD (n = 51)
Dialysis
(n = 41)
p* p#
30-Day events
MACE 6 (1.8) 1 (0.8) 1 (0.9) 3 (6) 1 (2.4) 0.12 0.1
Death 3 (0.9) 0 0 3 (6) 0
Myocardial infarction 2 (0.6) 1 (0.8) 1 (0.9) 0 0
Q-wave myocardial infarction 1 (0.3) 1 (0.8) 0 0 0
Non Q-wave myocardial infarction 1 (0.3) 0 1 (0.9) 0 0
Target vessel revascularization 3 (0.9) 1 (0.8) 1 (0.9) 0 1 (2.4) 0.81
Percutaneous coronary intervention 2 (0.6) 1 (0.8) 1 (0.9) 0 0
Coronary artery bypass surgery 3 (0.9) 1 (0.8) 1 (0.9) 0 1 (2.4) 0.81
Stent thrombosis 2 (0.6) 1 (0.8) 1 (0.9) 0 0
2-Year events
Follow up, day 615± 214 565± 227 545± 218 608± 203 0.14 0.49
MACE 58 (17.3) 13 (9.7) 17 (15.2) 15 (30) 13 (31) 0.001 0.0003
Death 9 (2.7) 0 1 (0.9) 6 (12) 2 (4.8) <0.0001 0.0001
Myocardial infarction 7 (2.0) 2 (1.5) 2 (1.8) 2 (4) 1 (2.4) 0.76 0.62
Q-wave myocardial infarction 2 (0.6) 2 (1.5) 0 0 0 0.38 0.94
Non Q-wave myocardial infarction 5 (1.5) 0 2 (1.8) 2 (4) 1 (2.4) 0.22 0.25
Target vessel revascularization 43 (12.8) 11 (8.3) 14 (12.5) 9 (18) 9 (21.4) 0.09 0.04
Percutaneous coronary intervention 40 (11.9) 11 (8.3) 14 (12.5) 7 (14) 8 (19) 0.27 0.18
Coronary artery bypass surgery 6 (1.8) 1 (0.8) 2 (1.8) 2 (4) 1 (2.4) 0.52 0.43
Stent thrombosis 5 (1.5) 2 (1.5) 2 (1.8) 1 (2) 0 0.85 0.71
Data are presented as number of patients (%) or mean± SD.
CKD, chronic kidney disease; MACE, major adverse cardiovascular events.
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all cases of stent thrombosis were observed within 100 days
after stent implantation (Fig. 2).
MACE and mortality rates were signiﬁcantly higher
in the patients with GFR <60ml/min/1.73mm2 (12.3%
and 0.4%, respectively) than in the patients with
GFR 60ml/min/1.73mm2 (30.4% and 8.7%, respectively)
(Fig. 1C and D). In a Cox proportional hazards model, mod-
erate CKD patients were at an increased risk of MACE (HR
4.10; 95% CI, 1.95—8.63; p = 0.0002) compared to control
patients. Dialysis patients were also at a high risk of 2-year
MACE (HR 3.88; 95% CI, 1.80—8.40; p = 0.0006) compared
to control patients. After making adjustments for variables
with univariable differences, including age, sex, over body
weight, diabetes, insulin user, hypertension, anemia, and
low left ventricular ejection fraction, baseline renal func-
tion remained a signiﬁcant predictor of 2-year MACE (Fig. 3).
In comparison to control patients, mild CKD, moderate CKD,
and dialysis patients had adjusted HRs of 2.51 (95% CI,
1.01—6.24), 3.20 (95% CI, 1.07—9.60), and 4.19 (95% CI,
1.30—13.51), respectively, for 2-year MACE.
Discussion
In this study, we evaluated the relationship between degree
of renal function at baseline and long-term clinical outcomes
in CAD patients who underwent paclitaxel-eluting stent
implantation. The main ﬁndings of this study can be summa-
rized as follows: (1) patients with reduced renal function,
even mild CKD, were signiﬁcant predictors of adverse car-
a
m
d
t
Cml/min/1.73mm2.
iovascular events independently of baseline characteristics
nd treatments; (2) patients with GFR <60ml/min/1.73mm2
ad a signiﬁcantly increased rate of occurrence of 2-year
ardiac death; (3) angiographic restenosis rate and late
umen loss steadily increased with decreasing baseline renal
unction. As the results, a graded relationship was observed
etween lower renal function and increased TVR at 2 years
fter PCI.
Many studies have reported on higher mortality and
ardiovascular events in CKD patients after successful PCI
7—9]. The precise reasons for high mortality and cardiovas-
ular events are probably multifactorial. CKD patients are
enerally older and have higher prevalence of traditional
oronary risk factors as shown in the present study. How-
ver, a post hoc analysis of the PRESTO trial demonstrated
hat an association between CKD and cardiovascular events
as not signiﬁcant after adjusting for coronary risk factors
nown to be associated with mortality [16]. These ﬁndings
ay indicate that the factor CKD also represents other non-
raditional risk factors, such as the presence of anemia,
nﬂammation, oxidative stress, calcium—phosphate distur-
ance, and coagulation abnormalities [17,18]. The present
tudy demonstrated that reduced renal function remained
igniﬁcant even after making adjustments for the differ-
nces in baseline characteristics and medical treatment
mong the 4 groups. Speciﬁcally, we demonstrated that even
ild CKD was associated with an increased risk of cardiac
eath, myocardial infarction, or TVR as compared to con-
rol patients. In the era of BMS, Best et al. found that mild
KD patients have increased mortality rate at 1 year after
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Control             : GFR ≥90ml/min
Mild CKD          : GFR 89-60ml/min
Moderate CKD : GFR 59-20ml/min
Dialysis
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Post hoc angiographic analysis of the TAXUS-IV trial showed
that mean late lumen loss after paclitaxel-eluting stent
implantation varied between 0.37 and 0.42mm at all lev-
els of renal impairment. Results from the above-mentioned
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1igure 1 Kaplan—Meier estimates of survival freedom from MA
urve for freedom from MACE (C) and cardiac death (D) among
KD, chronic kidney disease; GFR, glomerular ﬁltration rate; M
uccessful PCI compared to patients with normal renal func-
ion [19]. Although a difference was not observed in cardiac
ortality rates between the control and mild CKD patients
n the present study, a signiﬁcantly higher cardiac mortality
ate was observed in moderate CKD and dialysis patients.
he reason for cardiac death in patients with moderate CKD
nd dialysis was contributed by the high incidence of car-
iac failure. A frequent peculiarity of pathological changes
n moderate CKD and dialysis patients is plaque calciﬁcation
nd increased intima and media thickness [20]. In large con-
uit arteries, thickening and calciﬁcation of the media layer
esult in left ventricular afterload with the development of
eft ventricular hypertrophy [21]. These changes promote
hronic myocardial ischemia due to an increased myocardial
xygen demand, and a deterioration of coronary perfusion
nd sub-endocardial blood ﬂow distribution [22]. We found
hat an interventional strategy with DES is still ineffective
n reducing cardiac mortality, and that the usage of statins,
eta blockers, and angiotensin-II receptor blocking agents is
till low for moderate CKD and dialysis patients. Therefore,
t is conceivable that optimal medical intervention might be
ble to improve the poor outcomes in CKD patients [10].
ncidentally, there is a concern about the possible incidence
f late stent thrombosis after DES implantation, but we did
ot ﬁnd any associations between cardiac death and stent
hrombosis during 2 years after PCI.
F
K
t
yA) and cardiac death (B) according to GFR at admission. Survival
nts with GFR <60 vs. GFR 60ml/min/1.73mm2 at admission.
major adverse cardiac events.
VR and CKD in the DES eraigure 2 Cumulative incidence of stent thrombosis.
aplan—Meier curve shows the survival free from deﬁnite stent
hrombosis for the overall cohort. The incidence was 1.5% at 2
ears.
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Figure 3 Multivariable adjustment for the association of CKD
stage with the risk of cardiac death, myocardial infarction, or
target vessel revascularization. Hazard ratio (HR) (squares) and
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R95% conﬁdence interval (CI) (horizontal bars) are shown. CKD,
chronic kidney disease; MACE, major adverse cardiovascular
events.
study showed that, TVR at 1 year was 6.9%, 8.0%, and 6.6% in
the patients with normal renal function, mild CKD, and mod-
erate CKD without dialysis, respectively [23]. In contrast,
the present study showed that late lumen loss increased to
0.60mm in patients with mild CKD. Although late lumen loss
was identical between moderate CKD and dialysis groups, it
rose to 0.86mm for each group. These graded relationships
affected the TVR rate at 2 years after PCI. Higher TVR rates
in the present study may be related to ‘‘real world’’ popula-
tion characteristics more frequently with diabetic patients
and complex lesions. On comparing moderate CKD patients
in the TAXUS-IV trial with those in our study, we found that
the numbers of diabetic patients were 22.4% and 69%, and
those of patients with B2/C complex lesions were 57.9% and
85%, respectively [23].
A recently published meta-analysis of the results of
6 completed clinical trials, in which a total of 3669
patients were randomly assigned to sirolimus-eluting stent
vs. paclitaxel-eluting stent showed signiﬁcant differences
in target lesion revascularization rates (5.1% vs. 7.8%,
p < 0.001) favoring the sirolimus-eluting stent [11]. In CKD
patients, however, few data directly compared the long-
term outcomes of sirolimus- and paclitaxel-eluting stents
[24]. Previous studies have reported lower TVR rates rang-
ing from 6.9% to 13% in patients with moderate CKD after
sirolimus-eluting stent implantation [9,25], whereas moder-
ate CKD patients in the present study showed a TVR rate
of 18% after paclitaxel-eluting stent implantation. However,
the differences in TVR rates observed between moderate
CKD patients with either sirolimus- or paclitaxel-eluting
stents were not observed in dialysis patients treated with
the 2 types of stents. Most studies have reported higher
TVR rates in dialysis patients after treatment with sirolimus-
eluting stent. TVR or target lesion revascularization rates
ranged from 17% to 32.3% [9,26,27], whereas a 2-year TVR
rate of 21.4% was observed after treatment with paclitaxel-
eluting stent. These ﬁndings indicate that although the
advent of DES has remarkably reduced the incidence of TVR
in several high risk subsets, especially in patients on dialysis,
there still remains a challenging subset in the era of DES.67
The analyses of the present study should be interpreted
ith caution because of the relatively small population, and
he use of data from a single center. Although all patients
ere scheduled for a follow-up angiogram at 8—12 months
fter PCI, the rate of follow-up angiography was not equal
mong the 4 groups. In particular, it was lower for mod-
rate CKD patients, because of the need to avoid the risk
f contrast-induced nephropathy. In addition, although con-
inuation of optimal medical therapy, including statins and
ngiotensin-II receptor blocking agents, has a potential to
mprove long-term outcomes, we lacked data about the
etail of medical treatments during 2 years after PCI, such
s discontinuation of medical treatments.
In conclusion, we demonstrated that despite treatment
f CAD patients with paclitaxel-eluting stent, cardiac death
nd TVR rates were signiﬁcant in moderate CKD and dialysis
atients, further suggesting that CKD still has an adverse
mpact on long-term outcomes of CAD patients treated
ith DES implant. Therefore, identiﬁcation of patients with
arly-stage CKD is crucial. Aggressive medical checkups and
reatment of CAD are warranted in the earlier stage of CKD.
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